Cryoport (NASDAQ:CYRX) Trading Down 7.4%

Cryoport, Inc. (NASDAQ:CYRX – Get Rating) shares were down 7.4% during trading on Wednesday . The company traded as low as $18.63 and last traded at $18.72. Approximately 76,788 shares were traded during trading, a decline of 80% from the average daily volume of 386,596 shares. The stock had previously closed at $20.21.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Cryoport in a research report on Friday, April 21st.

Cryoport Price Performance

The company has a debt-to-equity ratio of 0.76, a current ratio of 14.54 and a quick ratio of 13.90. The company has a fifty day moving average price of $21.28 and a 200 day moving average price of $20.49. The company has a market capitalization of $868.45 million, a P/E ratio of -24.45 and a beta of 1.32.

Cryoport (NASDAQ:CYRX – Get Rating) last released its earnings results on Thursday, May 4th. The consumer goods maker reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $62.82 million during the quarter, compared to the consensus estimate of $62.15 million. Cryoport had a negative return on equity of 4.90% and a negative net margin of 11.91%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.31) earnings per share. On average, sell-side analysts forecast that Cryoport, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling at Cryoport

In other Cryoport news, insider Mark W. Sawicki sold 1,476 shares of the business’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $20.14, for a total transaction of $29,726.64. Following the sale, the insider now directly owns 63,032 shares of the company’s stock, valued at approximately $1,269,464.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Mark W. Sawicki sold 1,476 shares of the company’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $20.14, for a total value of $29,726.64. Following the transaction, the insider now directly owns 63,032 shares of the company’s stock, valued at $1,269,464.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 3,798 shares of the stock in a transaction on Monday, March 13th. The stock was sold at an average price of $20.14, for a total transaction of $76,491.72. Following the transaction, the chief executive officer now directly owns 435,588 shares in the company, valued at $8,772,742.32. The disclosure for this sale can be found here. Insiders have sold a total of 179,743 shares of company stock valued at $3,879,341 in the last three months. 10.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cryoport

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in Cryoport by 19.4% during the first quarter. JPMorgan Chase & Co. now owns 33,229 shares of the consumer goods maker’s stock valued at $1,160,000 after acquiring an additional 5,398 shares during the period. US Bancorp DE raised its position in Cryoport by 16.6% in the first quarter. US Bancorp DE now owns 24,191 shares of the consumer goods maker’s stock worth $844,000 after purchasing an additional 3,448 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Cryoport by 50.3% in the first quarter. PNC Financial Services Group Inc. now owns 8,053 shares of the consumer goods maker’s stock worth $280,000 after purchasing an additional 2,696 shares in the last quarter. AlphaCrest Capital Management LLC raised its position in Cryoport by 64.3% in the first quarter. AlphaCrest Capital Management LLC now owns 11,007 shares of the consumer goods maker’s stock worth $384,000 after purchasing an additional 4,307 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in Cryoport by 59.9% in the first quarter. MetLife Investment Management LLC now owns 21,874 shares of the consumer goods maker’s stock worth $764,000 after purchasing an additional 8,194 shares in the last quarter. 88.66% of the stock is owned by institutional investors and hedge funds.

Cryoport Company Profile

(Get Rating)

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.